Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moyle

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
HIV Medicine|July 18, 2008
Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyD Maitland, A Jackson, J Osorio, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2014
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudyGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
Clinical and Experimental Immunology|May 25, 2013
Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapyA A Herasimtschuk, B R Hansen, A Langkilde, et al.
Antiviral Therapy|May 1, 2001
Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing CommitteeG J Moyle, E Bouza, F Antunes, et al.
Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence|February 3, 2026
Examining links between somatosensation and cognition in children with hemiplegic cerebral palsyKassandra M Hewitt, Donna M Bayliss, Belinda A McLean, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2000
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapyG V Matthews, G J Moyle, S Mandalia, et al.
British Journal of Clinical Pharmacology|September 5, 2002
Interaction between saquinavir soft-gel and rifabutin in patients infected with HIVG J Moyle, N E Buss, T Goggin, et al.
AIDS Care|April 9, 2011
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenzVanessa Cooper, Graeme J Moyle, Martin Fisher, et al.
The Journal of Infectious Diseases|February 18, 2005
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infectionGraeme J Moyle, Adrian Wildfire, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2005
Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysisGraeme J Moyle, Karen Schoelles, Kyle Fahrbach, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
HIV Medicine|July 18, 2008
Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyD Maitland, A Jackson, J Osorio, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 9, 2014
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudyGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
Clinical and Experimental Immunology|May 25, 2013
Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapyA A Herasimtschuk, B R Hansen, A Langkilde, et al.
Antiviral Therapy|May 1, 2001
Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing CommitteeG J Moyle, E Bouza, F Antunes, et al.
Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence|February 3, 2026
Examining links between somatosensation and cognition in children with hemiplegic cerebral palsyKassandra M Hewitt, Donna M Bayliss, Belinda A McLean, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2000
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapyG V Matthews, G J Moyle, S Mandalia, et al.
British Journal of Clinical Pharmacology|September 5, 2002
Interaction between saquinavir soft-gel and rifabutin in patients infected with HIVG J Moyle, N E Buss, T Goggin, et al.
AIDS Care|April 9, 2011
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenzVanessa Cooper, Graeme J Moyle, Martin Fisher, et al.
The Journal of Infectious Diseases|February 18, 2005
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infectionGraeme J Moyle, Adrian Wildfire, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2005
Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysisGraeme J Moyle, Karen Schoelles, Kyle Fahrbach, et al.
Pageof 8